Annual Report **2025**

TEXAS A&M
INNOVATION

innovation.tamus.edu

Key Highlights

Achieved a 29% increase in executed license and option agreements

Received a record number of invention disclosures in the last five years

Launched the New Ventures team

Hosted Innovation Forward, a major outreach event that unveiled Future12

What We Do

Texas A&M Innovation supports inventors and commercializes innovations across The Texas A&M University System, using a rigorous process to guide projects from new innovations through market commercialization.

Our focus is on protecting A&M System intellectual property, increasing inventor engagement through education and outreach, building industry partnerships, supporting startups and entrepreneurial ventures, and facilitating access to critical resources to accelerate commercialization of A&M System intellectual property.

Through our work we strive to promote regional economic development and positively impact the lives of people locally, nationally, and globally.

PERFORMANCE METRICS

271 Invention Disclosures



67 Total License & Option Agreements



67 U.S Patents Issued



9 Startups



$8M in Licensing Revenue



LICENSING AND COMMERCIALIZATION

Highlights

Technology licensing activity continued to rise this year, with a 29% increase in the number of deals executed. Below are a few of the promising innovations from the A&M System's license and option agreements this year.

- **Next Generation Materials for Muscle Repair:** Time-Released Ion Matrix (TRIM) is an inorganic biomaterial platform that uses localized ion release to stimulate regenerative gene expression and restore damaged soft tissue. It provides broad potential in soft tissue applications, from treating human muscle diseases to repairing animal injuries and even serving as a carrier for stem cell therapies.
- **Plant-Based Technology for Microplastic Removal**: Researchers developed a plant-based technology that uses polysaccharides derived from plants as flocculants to bind to and remove microplastics from water. This method delivers a safe, sustainable alternative to chemical treatments, with potential for large-scale deployment in wastewater facilities.
- **Advanced Sorghum for Diverse Markets:** The Texas A&M AgriLife Research Sorghum Breeding Program develops advanced sorghum lines for hybrids adaptable to diverse environments in Texas, U.S., and global markets. Beyond livestock feed, these innovations support human food products and bioenergy feedstocks. Increased utilization has driven higher licensing revenue this year.
- **Ocean Wave Energy Conversion System**: The Global Perpetual Energy (GPE) Ocean Blanket uses hydroelastic resonance to efficiently capture power from complex ocean wave motion. It enables cost-effective, utility-scale electricity generation while also adding protection for offshore structures by mitigating wave impact.

Targeted Initiatives Accelerating Innovations

We provided **Market Intelligence Support** for invention evaluation, market discovery and analysis, licensee research, company outreach, and development of more than 140 marketing materials to be shared with potential licensees.

We directed **Commercialization Funding** toward high-potential technologies, addressing key development needs and enhancing their readiness for follow-on investment or licensing deals. Invested over $740,000 in 14 select projects to support further development toward commercialization.

Development Milestone Achievement

Dr. Scott Dindot in research lab (second from right).

Phase 3 Human Trials Launched for First-Ever Angelman Syndrome Therapy. GTX-102, the first therapeutic drug developed for Angelman syndrome (AS), has entered Phase 3 human clinical trials, marking a major milestone in the path toward treatment for this rare genetic disorder. GTX-102 was discovered by Texas A&M University researcher Dr. Scott Dindot and is being developed by Ultragenyx. If successful, GTX-102 would become Texas A&M's first FDA-approved drug on the market. (Learn more)

INNOVATOR ENGAGEMENT

Education, Outreach, and Engagement

Texas A&M has seen a 34% increase in the number of inventors submitting disclosures over the past 5 years, demonstrating a strong upward trend in harvesting innovation activity across the A&M System. In FY25 alone, 571 inventors submitted disclosures, and Texas A&M Innovation-hosted events saw a 34.7% increase in average participation compared to the previous year. Continued outreach efforts contribute to the growing pipeline of new ideas and discoveries from Texas A&M innovators.

Chancellor's Innovation Award Winner

Vishal Gohil, Ph.D.,
Professor of Biochemistry & Biophysics, College of Agriculture and Life Sciences, Texas A&M University

"This breakthrough therapy offers new hope for children and families facing the devastating effects of Menkes disease." - Dr. Gohil

- **Breakthrough Discovery**: Identified a new use for the compound elesclomol in delivering copper into mitochondria, correcting biochemical defects associated with genetic copper deficiency.
- **Life-Changing Impact:** Shows strong promise as a treatment for Menkes disease, a rare pediatric disorder. Children in compassionate-use cases have reached developmental milestones once thought impossible.
- **Path to Market:** Licensed to Engrail Therapeutics, with FDA Orphan Drug and Rare Pediatric Disease designations accelerating clinical development. (Learn more)

InnovationU and Innovation Connect

Hosted three educational seminars and two networking events, engaging over 590 faculty, staff, students, and aspiring entrepreneurs on topics including strategies for balancing patenting and publishing, and a technology showcase in collaboration with TAMU's Advancing Discovery to Market program.

Local and Regional Outreach

Participated in thirteen local meetings, events, and workshops, and traveled for eight visits to A&M System universities statewide. Gained over 1,000 new followers on LinkedIn across Texas and the USA, surpassing 2,200 followers. Distributed over 143,945 emails through marketing campaigns, with over 45% opened.

Innovation Awards

Celebrated inventors across the A&M System who achieved patent protection for their work within the previous calendar year at our annual awards luncheon. This year we recognized 54 inventors from Texas A&M University, Prairie View A&M University, Texas A&M University-Corpus Christi, and Texas A&M University-Kingsville.

NEW VENTURES

With the launch of our New Ventures team, we began building a scalable infrastructure to guide university-born startups from discovery to market success.

STARTUP HEADLINES

- **Sano Chemicals Completes Phase 1 Clinical Trial for Occidiofungin:** Texas A&M faculty startup Sano Chemicals successfully completed Phase 1 clinical trials for Occidiofungin, demonstrating safety and tolerability among participants. Occidiofungin is a first-in-class antifungal therapy targeting recurrent vulvovaginal candidiasis (RVVC) with the potential to improve the lives of millions of women worldwide. (Learn more.)
- **Startup Humanate wins big while tackling healthcare workforce challenge:** Humanate won the grand prize at the 2025 Texas A&M New Ventures Competition, standing out among rising startups from across the state. This digital health company spun out of Texas A&M is poised to improve patient care with its innovative AI medical receptionist technology. (Learn more.)
- **Pulmotect Advances Phase 2 Clinical Trial for PUL-042:** Biotech startup Pulmotect began dosing in a Phase 2 clinical trial of its inhaled therapy, PUL-042, aimed at preventing severe respiratory infections in immunocompromised cancer patients. Backed by an $8.9M CPRIT grant, this milestone advances a promising therapy jointly invented at Texas A&M and UT MD Anderson Cancer Center. (Learn more.)
- **FluxWorks Space Raised Initial Funding & Selected to Inaugural Cohort of Plug and Play Tech Center:** FluxWorks, a provider of novel magnetic gear technology for aerospace and industrial applications, was selected out of more than 40 startups to participate in the first cohort of companies in the newly launched Plug & Play Tech Center in Bryan/College Station. In addition, the company successfully raised a $4.54M round. (Learn more.)

ACROSS THE STATE AND BEYOND

This year we engaged more than 1,300 internal and external stakeholders through various events and initiatives throughout the State. Below are a few examples from this year's efforts.

Innovation Forward

The event drew over 440 industry leaders, policymakers, and investors from multiple countries, aimed at elevating the institution's global visibility and reinforcing its leadership in technology innovation. A highlight was the unveiling of Future12, a strategic collaboration with the Texas A&M Association of Former Students to harness insights from industry leaders to predict 12 up and coming technological advancements.

Texas A&M New Ventures Competition

The 11th Annual Texas A&M New Ventures Competition (TNVC) brought together 20 startups from across Texas to compete for up to $1.9 million in prizes. We hosted more than 200 entrepreneurs, investors, and regional ecosystem contributors. This year, Bryan-based Humanate Digital took home the grand prize. To date, TNVC has awarded over $5 million in prizes and its past competitors have raised more than $706 million in investments, reinforcing its role in driving innovation across Texas and beyond.

FY2025 FINANCIAL SUMMARY

The following provides a summary of IP-related financials for The Texas A&M University System, managed by Texas A&M Innovation.

TAMUS SUMMARY	

REVENUE	
Gross IP Revenue to TAMUS*	$ 8,107,986
Patent Reimbursement Revenue*	$ 947,445
Total Revenues	$ 9,055,431

EXPENSES	
IP Revenue Distributed to TI	$ 3,974,599
Commercial Development Fund Distribution	$ 350,289
Other IP Revenue Distributed**	$ 3,077,571
Patent Expenses	$ 3,406,673
Bad Debt Expense	$ 1,359,513
Total Expenses	$ 12,168,645

NET INCOME (LOSS)	$ (3,113,214)

*The Texas A&M University System realizes licensing and patent reimbursement revenue upon invoice creation.

**Other IP Revenue Distributed includes inventor shares, grandfathered distribution policy shares, member-owned trademarks, and contractually obligated distributions to third parties.

FY2025 FINANCIAL SUMMARY

The following provides a summary of office operational expenses for Texas A&M Innovation.

TI SUMMARY	

REVENUE	
IP Revenue Distributed to TI	$ 3,974,599
Commercial Development Fund Distribution	$ 350,289
Misc - Event Sponsorship & Other	$ 119,133
Total Revenue	$ 4,444,021

EXPENSES	
Payroll & Incentives	$ 4,695,967
Travel, Training, Meetings, Memberships	$ 118,045
Marketing, Advertising, Events	$ 1,052,468
Location Expenses, Equipment, IT-Software-Services	$ 855,138
Commercialization Support Funding	$ 740,883
Misc - Contracts, Consulting, Fees, & Other	$ 463,680
Total Expenses	$ 7,926,181

NET INCOME (LOSS)	$ (3,482,160)